Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...
Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...
Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...
Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...
Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, its chief executive said on Wednesday, but it is confident its business is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback